reason report
solid quarter cf franchis grow new pipelin emerg
result beat consensu revenu ep driven
strong symdeko uptak us better orkambi revenu
lower expect oper expens total cystic fibrosi cf
product revenu beat consensu grow
sequenti yoy symdeko launch captur
signific convers new start momentum
continu next quarter better doublet take
us market compani guid total cf product revenu
compar estim
consensu combin non-gaap
sg expens compar estim
consensu revenu guidanc appear
incorpor signific sequenti revenu declin
recoveri later year channel inventori stabil
new approv add demand much-anticip phase
trial second tripl combin expect read later
quarter provid continu support stock compani
remain commit file first tripl combin nda applic
mid-year continu suggest intend develop addit
tripl combin may optim dose conveni
toler attribut beyond cf compani program
pain rare diseas begin captur analyst
investor attent find hard attribut much real valu
stage given remain rel long develop trajectori
slower symdeko ramp higher oper expens price
updat revenu expens forecast
base recent quarter manag guidanc
commentari total revenu forecast decreas
forecast larg unchang
chang primarili base slightli slower revenu
trajectori symdeko partial off-set faster sale
ramp-up tripl combin revis total revenu
forecast consensu
recent consensu estim beyond oper
expens estim unchang increas
base higher sg forecast base
chang pro-forma dilut ep estim decreas
revis ep estim consensu
consensu recent
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
consensu updat multipl industri peer
revis price target vs previous maintain
outperform rate
new price target vertex rate stock outperform thesi
base expect continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio well probability-adjust effect competit
entri beyond consid competitor forecast valuat
believ develop path time market challeng vertex well posit
partner acquir show promis flirt profit past vertex
seem determin maintain recent recov profit appear capabl grow
oper margin even higher beyond compani still aspir
discov develop drug categori larg diversifi invest associ
expens risk thesi valuat howev potenti sizabl near-term
growth stock offer strong valuat upsid potenti next month
strong orkambi perform drove revenu beat vertex total cf product revenu
beat consensu forecast sale orkambi drove top-
line beat bounc back revenu amid on-going launch symdeko
manag comment demand symdeko came patient previous
discontinu never initi orkambi switcher orkambi kalydeco appear
fear cannib orkambi symdeko stabil although clear
whether switch symdeko acceler near futur symdeko sale
consensu estim estim grow sequenti
sale kalydeco consensu estim
ep beat driven higher revenu in-lin oper expens gross margin
line consensu estim vertex non-gaap total oper expens
consensu line forecast non-gaap expens
consensu estim off-set non-gaap sg
quarter vs consensu vs compani tax rate
non-gaap dilut ep come consensu estim
in-lin guidanc sens conservat cf product revenu guidanc
consist recent consensu compani guid non-gaap
 sg expens also bracket consensu estim
compani explain call current revenu guidanc includ revenu
three cf product exist indic plu potenti revenu symdeko
patient year old expect approv year countri reimburs
secur increment revenu contribut new reimburs addit countri
come upsid compani may choos updat guidanc accordingli new
opportun materi view revenu guidanc easili achiev annual
revenu alon without consid continu growth symdeko beyond
compani expect cf revenu continu grow base expect launch tripl
combin significantli higher penetr diagnos cf popul current
cf revenu grow expect oper margin continu expand toward
industri peak
ex-u reimburs battl continu drag vertex disclos call current
cf patient treat vertex drug split us
outsid us reimburs battl vertex sever import eu
countri franc uk show sign immedi resolut expect
pressur reimburs medicin increas approv symdeko/symkevi
europ intens tripl approv manag reiter
disagr nice evalu methodolog appear steadfast refus
chang stanc compani also dismiss threaten compulsori licens
suggest recent emerg uk
second tripl combin data nda file regard anticip phase
readout second tripl combin compani guid top-lin
readout reiter timelin nda file later manag
express strong confid timelin good visibl on-going studi
base time enrol complet late novemb
manag prior disclosur believ vertex data end
non-cf pipelin slowli attract invest attent vertex current invest
four emerg diseas area provid long-term pipelin diversifi cf
franchis consist antitrypsin defici pain sickl cell disease/beta
thalassemia focal segment glomerulosclerosi manag explain first
candid defici enter clinic late second candid also
expect move clinic develop year compani clarifi two
candid two iter molecul class expect
synergist vertex expect conduct sever quick earli stage studi identifi best
candid move forward overal compani view program reason
effici given avail potenti approv biomark circul level
pain program manag state may abl develop commerci
product specialti indic like acut pain small fiber neuropathi
would inclin seek partner primari care market chronic inflammatori pain
slower symdeko ramp higher oper expens price target
updat revenu expens forecast base recent quarter manag
guidanc commentari total revenu forecast decreas
forecast larg unchang chang
primarili base slightli slower revenu trajectori symdeko partial off-set
faster sale ramp-up tripl combin revis total revenu forecast
consensu recent consensu estim
beyond oper expens estim unchang increas
base higher sg forecast base chang
pro-forma dilut ep estim decreas revis ep estim
consensu consensu
recent consensu updat multipl industri peer revis price target
maintain outperform rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo appli current ep estim
discount back year compani cost equiti give valu one year
use averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit
svb leerink llc partner research compani file
svb leerink vertex select balanc sheet cash-flow item
million
total liabil sharehold equiti
chang asset liabil
chang market secur
purchas treasuri stock
chang capit stock net
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
svb leerink llc partner research compani file
brand
type event
event trial detail
date known
up/down
leerink view
phase iib dose rang studi patient
phase trial cf
nda file cf patient year old
fda approv cf patient year old
svb leerink llc research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
termin cash flow growth rate
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
